	Application No.	Applicant(s)
Notice of Allowability	10/749,181	HOCTOR ET AL.
	Examiner	Art Unit
	Jaworski Francis J.	3768
	Jawoiski Flaticis J.	3708
The MAILING DATE of this communication apper All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communicat GHTS. This application is subject	application. If not included ion will be mailed in due course. THIS
1. This communication is responsive to Rule 116 Amdt 5/12/0	<u>06</u> .	
2. The allowed claim(s) is/are <u>1-3,5-23 and 25-49</u> .		
3. Acknowledgment is made of a claim for foreign priority un	der 35 U.S.C. § 119(a)-(d) or (f).	
a) All b) Some* c) None of the:		
 Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		ly complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftspers		O-948) attached
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date	Amendment / Comment or in the	e Office action of
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5 Notice of Informa	I Patent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 🔲 Interview Summa	iry (PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail [8), 7. Examiner's Amen	Date ndment/Comment
Paper No./Mail Date 6-22-2004 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's State	ment of Reasons for Allowance
of biological ivialerial	9.	. /
		Erancis J. Paworski Primary Examiner

Application/Control Number: 10/749,181

Art Unit: 3768

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

1) Insofar as this application included method and apparatus claims which effect computational algorithms yet do not involve a physical transformation of matter the claims were evaluated for statutory content with respect to 35 USC 101 in accordance with current PTO guidelines promulgated in the Official Gazette 11/22/05.

All claims were considered to be statutory insofar as they are associated with the concrete and tangible process of transmitting beams of ultrasonic wave energy towards and receiving reflections from an artery under test and provide a concrete result of a blood pressure or pulse wave velocity measurement.

The following art is cited as of interest:

Asmar (US6511436, of record) does in fact use reflected wave energy in an ultrasonic pulse wave velocity measurement as discussed col. 7 line 39 – col. 8 line 9 however this is a correction for anatomic distance variations in order to effect pulse wave velocity measurement. In other words the pulse wave reflections are not corrected or compensated for, rather they are used to determine true distance from the heart to peripheral measurement sites for conventional pulse wave velocity determinations.

Hatschek (US5309916) is directed to a method and system which uses ultrasound (col. 5) to determine flow or pulse wave velocity by computational process which uses the measured time shift between primary and reflected arterial pulse waves as the primary pulse wave velocity measurement, see col.7 line 35 – col. 8 line 28 and

Application/Control Number: 10/749,181

Art Unit: 3768

col. 23 lines 29 – 54. The reflected arterial pulse wave is therefore not corrected for since it, in and of itself constitutes part of the measurement result.

Mitchell (US6331162) is directed to a pulse wave velocity measurement with mention of ultrasound Doppler as alternative to pulse pletyysmographic sensor input however the pulse wave foot is measured by the preferred PPG device since it is stated to be immune from reflection presence, in effect a teaching away from reflection correction of any sort, see col. 6 lines 9 – 13.

Goodman (US6616613) is directed to overcoming prior art shortcomings to the use of reflected wave components in and of themselves to parameterize vascular health by photoplethysmographic techniques, see col. 2 line 11 – col. 3 line 24, col. 14 line 40 – col. 15 line 44, col. 23 lines 48 – 62.

Meister et al (US5099852) teaches ultrasound pulse wave velocity measurement including an adjustment step 12 however this constitutes mathematical least squares iteration unrelated to reflected arterial pulse waves.

Rantala (US7029447) is directed to using an impedance cardiogram with a peripheral pulse plethysmographic sensor where the sensor threshold amplitude is adjusted to correct for a reflected wave component, see col7 lines 14 – 19 and col. 9 – 10 pulse detection portion.

None of the prior art, alone or in combination suggests or teaches a method or apparatus which corrects for reflected arterial pressure wave effects during ultrasound pulse wave velocity measurements, and the prior art either used reflection effects as a characterizing phenomenon or 'worked around' reflected effects as a perturbance in

contradistinction to applicants' technique inter alia paras [0021] and [99 – 137] where artery pulse pressure wave reflection effects are characterized and corrected for.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication should be directed to Jaworski Francis J. at telephone number 571-272-4738.

FJJ:fjj

060806

Francis J. Jaworski Primary Examiner